Tags : Kadmon

PharmaShots Weekly Snapshot (December 23-27, 2019)

1. Luye Pharma Reports Submission of NDA to the US FDA for LY03005 Published: Dec 26, 2019 | Tags: FDA, Luye Pharma, LY03005, NDA, reports, Submission, US 2. Immunomedics Reports the US FDA’s Acceptance of BLA for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer Published: Dec 26, 2019 | Tags: Acceptance, BLA, FDA, Immunomedics, […]Read More

Kadmon and Meiji Collaborate to Form JV for the Development

Shots: Kadmon to receive ~$29M as development, regulatory & commercial milestones with royalties on sales of KD025 in Japan and certain other Asian countries The JV, named as Romeck Pharma has the HQ in Japan with shared oversight between Kadmon and Meiji KD025 is ROCK2 inhibitor with the potential to treat inflammatory and fibrotic diseases, […]Read More